CLINICAL TRIALS PROFILE FOR OXYTOCIN

All Clinical Trials for oxytocin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004363 ↗	Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus	Completed	Northwestern University		1995-12-01	OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00004363 ↗	Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus	Completed	National Center for Research Resources (NCRR)		1995-12-01	OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00107874 ↗	Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-scheduled Cesarean Section	Completed	Basel Women’s University Hospital	Phase 2	1999-01-01	Postpartum hemorrhage (PPH) ranks among the leading causes of maternal morbidity and mortality, both in developed and developing countries. With this trial, we sought to determine the effectiveness of oral misoprostol as an uterotonic drug in comparison with intravenous oxytocin, in patients with a low risk of PPH undergoing non-scheduled Cesarean section. We therefore compared the intra- and postoperative blood loss, as well as drug related side effects in patients, treated by the same surgical and anesthesiological team in one institution.
NCT00107874 ↗	Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-scheduled Cesarean Section	Completed	University Hospital, Basel, Switzerland	Phase 2	1999-01-01	Postpartum hemorrhage (PPH) ranks among the leading causes of maternal morbidity and mortality, both in developed and developing countries. With this trial, we sought to determine the effectiveness of oral misoprostol as an uterotonic drug in comparison with intravenous oxytocin, in patients with a low risk of PPH undergoing non-scheduled Cesarean section. We therefore compared the intra- and postoperative blood loss, as well as drug related side effects in patients, treated by the same surgical and anesthesiological team in one institution.

Clinical Trial Conditions for oxytocin

Condition Name

Condition Name for oxytocin
Intervention	Trials
Postpartum Hemorrhage	85
Healthy	55
Schizophrenia	30
Oxytocin	21

Condition MeSH

Condition MeSH for oxytocin
Intervention	Trials
Hemorrhage	161
Postpartum Hemorrhage	142
Disease	37
Schizophrenia	33

Clinical Trial Locations for oxytocin

Trials by Country

Trials by Country for oxytocin
Location	Trials
United States	366
Egypt	87
Canada	64
China	49
France	34

Trials by US State

Trials by US State for oxytocin
Location	Trials
California	61
North Carolina	33
New York	31
Massachusetts	29
South Carolina	20

Clinical Trial Progress for oxytocin

Clinical Trial Phase

Clinical Trial Phase for oxytocin
Clinical Trial Phase	Trials
Phase 4	129
Phase 3	66
Phase 2/Phase 3	17

Clinical Trial Status

Clinical Trial Status for oxytocin
Clinical Trial Phase	Trials
Completed	391
Recruiting	118
Unknown status	97

Clinical Trial Sponsors for oxytocin

Sponsor Name

Sponsor Name for oxytocin
Sponsor	Trials
University of Electronic Science and Technology of China	40
Samuel Lunenfeld Research Institute, Mount Sinai Hospital	29
Cairo University	24

Sponsor Type

Sponsor Type for oxytocin
Sponsor	Trials
Other	1000
Industry	52
NIH	39